Figure 5

Snapshot of the web-based survival prediction application BreCanSurvPred. This snapshot shows the comparison of survival according to adherence to endocrine treatment for a 60-year old patient diagnosed with molecular subtype HER2 − /HR + in stage III. These survival probabilites are calculated up to 10 years after BC diagnosis. (Time: time since diagnosis [follow-up]; Percentage: percent survival at a certain Time ).